At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 21, 2026 at 10:30 ET
Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG), demonstrating statistically significant and clinically meaningful improvements in both primary and key secondary endpoints. The company has submitted a U.S. regulatory application and plans European filings in 2026, positioning cemdisiran as a potential first-in-class siRNA treatment for gMG with convenient quarterly dosing.
- Cemdisiran met primary endpoint with a 2.3-point placebo-adjusted improvement in MG-ADL score at week 24 (p<0.001)
- Achieved key secondary endpoint with a 2.8-point placebo-adjusted improvement in QMG score (p=0.002)
- 76.6% of cemdisiran patients had ≥3-point improvement in MG-ADL vs. 44.1% on placebo
- 48.4% of cemdisiran patients had ≥5-point improvement in QMG vs. 19% on placebo
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access